Topic: Diabetes Research Network, Eye
Conditions
Interventions
Mask, Patients will either wear a Light Mask or a dummy mask whilst they sleep at night.
Sponsors
Moorfields Eye Hospital NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects of either sex aged 18 years or over 2. Diagnosis of diabetes mellitus (type 1 or type 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: 2.1.Current regular use of insulin for the treatment of diabetes 2.2. Current regular use of oral antihyperglycaemic agents for the treatment of diabetes 2.3. Documented diabetes by ADA and/or WHO criteria 3. Best corrected visual acuity in the study eye better than 55 ETDRS letters (Snellen VA 6/18). 4. On clinical exam, retinal thickening due to early DMO not involving the central 100 µm of the macula characterised by presence of microaneurysm, exudates or oedema and OCT evidence of increased retinal thickness in at least 1 noncentral ETDRS zone of =320 µm. 5. Previous macular laser, intravitreal steroids or anti-VEGF treatment is permitted provided the last laser was done at least 4 months before date of recruitment. 6. Media clarity, pupillary dilation and subject cooperation sufficient for adequate fundus photographs 7. Ability to return for study visits 8. Ability to give informed consent throughout the duration of the study
Exclusion criteria
Exclusion criteria: The following exclusions apply to the study eye only (i.e. they may be present for the non study eye): 1. Centre-involving macular oedema defined as central subfield on OCT >300 um. 2. Macular oedema is considered to be due to a cause other than DMO. 3. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular oedema or alter visual acuity during the course of the study (e.g. vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, IrvineGass syndrome, etc). 4. History of treatment for DMO at any time in the past 4 months (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids, anti-VEGF drugs, or any other treatment) in the study eye 5. History of panretinal scatter photocoagulation in the study eye. 6. Active proliferative diabetic retinopathy in the study eye. 7. A condition that, in the opinion of the investigator, would preclude participation in the study. 8. Patients with history of insomnia or any other sleep disturbances. 9. Corneal scarring, vitreous opacities, severe asteroid hyalosis that would inhibit proper visualisation, inability to be positioned in front of the OCT device, inability to understand the requirements of the imaging, and nystagmus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OCT; Timepoint(s): difference between arms in the change from baseline in absolute thickness at the zone of maximum thickness | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Centre-involving macular oedema; Timepoint(s): Difference between arms in progression to centre-involving macular oedema. 2. Compliance of light masks.; Timepoint(s): Compliance rate of the light masks over 24 months 3. Macular laser treatment/anti-VEGF treatment.; Timepoint(s): Difference between the arms in the proportion requiring macular laser treatment/anti-VEGF treatment. 4. Occurrence of centre-involving macular oedema; Timepoint(s): Difference between arms in the time to occurrence of centre-involving macular oedema. 5. Progression of retinopathy as measured by ETDRS severity levels; Timepoint(s): Proportion of participants that show progression of retinopathy as measured by ETDRS severity levels. 6. Retinal thickness; Timepoint(s): Change in retinal thickness in each of the 9 ETDRS zones and macular volume. 7. Visual Acuity; Timepoint(s): Mean change in visual acuity. | — |
Countries
United Kingdom
Outcome results
None listed